

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 10, 2024

QUANTERIX CORPORATION

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-38319
(Commission File Number)

20-8957988
(IRS Employer
Identification No.)

900 Middlesex Turnpike
Billerica, MA
(Address of principal executive offices)

01821
(Zip Code)

(617) 301-9400
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	QTRX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On January 10, 2024, Masoud Toloue, the President and CEO of Quanterix Corporation (the "Company"), made a presentation at the 42nd Annual JP Morgan Healthcare Conference. The presentation included slides (the "Slides") containing preliminary, unaudited estimated financial information for the fourth quarter and year ended December 31, 2023 (the "Preliminary Financial Information"). A copy of the Slides is furnished as Exhibit 99.1 and is incorporated herein by reference.

The Preliminary Financial Information is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2023 and its results of operations for the quarter and year ended December 31, 2023. This Preliminary Financial Information is subject to completion of the Company's normal quarter and year-end close procedures. These procedures and the audit of the Company's financial statements for the year ended December 31, 2023 are ongoing and could result in changes to the Preliminary Financial Information.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Slides from January 10, 2024 Presentation containing the Preliminary Financial Information.
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

QUANTERIX CORPORATION

By: /s/ Vandana Sriram
Vandana Sriram
Chief Financial Officer

Date: January 11, 2024

Create the tools enabling discovery and better health



Unmatched Technology



>950 Instruments installed



Early penetration in multi-billion diagnostics



CLIA lab running validated neuro LDTs

\$121M

Revenue¹

\$18M

Cash burn¹

High **50%+s**

GAAP
Gross Margin²

Appr. **50%**

Non-GAAP
Gross Margin²

550+

Biomarkers

2,500+

Publications

 Nasdaq : QTRX

1. Preliminary unaudited full year results for 2023.

2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the high 50's, and non-GAAP gross margin percentage to be approximately 50%. GAAP gross margin does not include shipping and handling costs, which include freight and other activities costs associated with product shipments. Non-GAAP gross margin includes these shipping and handling costs.

Built to lead neuro decade

Strong Results	Double digit top-line growth¹	Non-GAAP GM² of appr. 50% Improvement of 1200 bps	Strong Balance Sheet >\$300M ¹ in net cash Annual cash burn ¹ down by >3x
Operational Leverage	Lab Services capability >0.75M tests per year (improvement of 50%)	Manufacturing capacity >4M tests per year (improvement of 300%)	Innovation rate >20 assays per year (development times reduced from >18 months to <6 months)
Clear Strategy	Research Power the neuro decade with unique biomarkers	Diagnostics Establish and grow the AD diagnostics business	

1. Preliminary unaudited full year results for 2023.

2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the high 50's, and non-GAAP gross margin percentage to be approximately 50%. GAAP gross margin does not include shipping and handling costs, which include freight and other activities costs associated with product shipments. Non-GAAP gross margin includes these shipping and handling costs.